Aligos Therapeutics Inc
NASDAQ:ALGS

Watchlist Manager
Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc
NASDAQ:ALGS
Watchlist
Price: 9.12 USD 5.56% Market Closed
Market Cap: 55.7m USD

Net Margin
Aligos Therapeutics Inc

-1 628.8%
Current
-1 199%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 628.8%
=
Net Income
-53.3m
/
Revenue
3.3m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Aligos Therapeutics Inc
NASDAQ:ALGS
55.7m USD
-1 629%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
330.5B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
164.4B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
137.2B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
127.5B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.7B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Aligos Therapeutics Inc
Glance View

Market Cap
55.7m USD
Industry
Biotechnology

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2020-10-16. The firm is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. The company uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. The company is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). The company developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The firm's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

ALGS Intrinsic Value
4.11 USD
Overvaluation 55%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 628.8%
=
Net Income
-53.3m
/
Revenue
3.3m
What is the Net Margin of Aligos Therapeutics Inc?

Based on Aligos Therapeutics Inc's most recent financial statements, the company has Net Margin of -1 628.8%.

Back to Top